Works matching IS 27696448 AND DT 2024 AND VI 3 AND IP 1
Results: 9
The biological essence of synthetic lethality: Bringing new opportunities for cancer therapy.
- Published in:
- Medcomm: Oncology, 2024, v. 3, n. 1, p. 1, doi. 10.1002/mog2.70
- By:
- Publication type:
- Article
Insight into Janus kinases specificity: From molecular architecture to cancer therapeutics.
- Published in:
- Medcomm: Oncology, 2024, v. 3, n. 1, p. 1, doi. 10.1002/mog2.69
- By:
- Publication type:
- Article
Targets of tumor microenvironment for potential drug development.
- Published in:
- Medcomm: Oncology, 2024, v. 3, n. 1, p. 1, doi. 10.1002/mog2.68
- By:
- Publication type:
- Article
Advances and applications of nanoparticles in cancer therapy.
- Published in:
- Medcomm: Oncology, 2024, v. 3, n. 1, p. 1, doi. 10.1002/mog2.67
- By:
- Publication type:
- Article
The hidden architects of glioblastoma multiforme: Glioma stem cells.
- Published in:
- Medcomm: Oncology, 2024, v. 3, n. 1, p. 1, doi. 10.1002/mog2.66
- By:
- Publication type:
- Article
Targeting iron–sulfur cluster assembly scaffold protein as a vulnerability in KRAS‐activated pancreatic ductal adenocarcinoma.
- Published in:
- Medcomm: Oncology, 2024, v. 3, n. 1, p. 1, doi. 10.1002/mog2.65
- By:
- Publication type:
- Article
Lysosome‐targeting chimera (LYTAC): A silver bullet for targeted degradation of oncogenic membrane proteins.
- Published in:
- Medcomm: Oncology, 2024, v. 3, n. 1, p. 1, doi. 10.1002/mog2.64
- By:
- Publication type:
- Article
Epigenetic regulation in cancer therapy: From mechanisms to clinical advances.
- Published in:
- Medcomm: Oncology, 2024, v. 3, n. 1, p. 1, doi. 10.1002/mog2.59
- By:
- Publication type:
- Article
Issue Information.
- Published in:
- Medcomm: Oncology, 2024, v. 3, n. 1, p. 1, doi. 10.1002/mog2.34
- Publication type:
- Article